New prostate cancer combo study halted early

NCT ID NCT03437941

NEW Terminated Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

First seen May 17, 2026 · Last updated May 17, 2026

Summary

This study tested a new drug (exicorilant) combined with a standard treatment (enzalutamide) in 39 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Detroit

Detroit, Michigan, 48201, United States
London

London, England, W1T7HA, United Kingdom
Madison

Madison, Wisconsin, 53792, United States
New York

New York, New York, 10065, United States
Portland

Portland, Oregon, 97239, United States
Scottsdale

Scottsdale, Arizona, 85258, United States
Southampton

Southampton, England, SO16 6YD, United Kingdom
Sutton

Sutton, Surrey, SM2 5PT, United Kingdom

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER